Disease landscape

Myasthenia Gravis clinical trials

Get alerts when Myasthenia Gravis trials change

159 active trials 95 recruiting 37 Phase 3 93 sponsors 23 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-15
Trial terminated
Trial terminated: Sponsor Decision
Study completion confirmed: August 2026 (last estimated February 2027)
NCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and… · Immunovant Sciences GmbH · Phase 3
2026-09-15
Primary completion pushed: 2026-09-30 → 2027-09
Completion pushed: 2026-09-30 → 2027-09
NCT06392386 A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With… · argenx · Phase 2/3
2026-09-12
Recruitment opened
NCT07596784 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized… · Alexion Pharmaceuticals, Inc. · Phase 3
2026-09-05
Enrollment closed, study ongoing
NCT06704269 Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized… · Novartis Pharmaceuticals · Phase 1/2
2026-09-02
Enrollment closed, study ongoing
Primary completion pushed: 2026-11-30 → 2026-12-30
Final enrollment: 128 participants (planned 100)
NCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach… · Cartesian Therapeutics · Phase 3
2026-08-27
Primary completion pushed: 2026-08-10 → 2026-10-05
NCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe… · UCB Biopharma SRL · Phase 2/3
2026-09-12
Trial sites expanded: 7 → 11 locations
NCT07463521 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With… · UCB Biopharma SRL · Phase 3
2026-08-25
Trial sites expanded: 2 → 7 locations
NCT07463521 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With… · UCB Biopharma SRL · Phase 3
2026-09-02
Trial sites expanded: 4 → 9 locations
NCT06987539 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of… · Amgen · Phase 2
2026-08-22
Trial sites expanded: 24 → 27 locations
NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… · argenx · Phase 2
2026-08-22
Trial sites expanded: 2 → 5 locations
NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… · TG Therapeutics, Inc. · Phase 2
2026-09-03
Trial sites expanded: 1 → 10 locations
NCT07215650 Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) · Candid Therapeutics · Phase 1
2026-09-04
Trial sites expanded: 1 → 9 locations
NCT07072988 Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia… · Centre Hospitalier Universitaire de Nice · Phase 4
2026-09-02
Trial sites expanded: 1 → 8 locations
NCT07411963 Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU… · Centre Hospitalier Universitaire de Nice
2026-09-02
Trial sites expanded: 1 → 11 locations
NCT07570589 Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With… · Centre Hospitalier Universitaire de Nice
2026-09-06
Trial status changed: Recruiting → Unknown
NCT06539169 FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases · xCures
2026-09-06
Trial status changed: Recruiting → Unknown
NCT06587867 Seronegative Myasthenia Gravis - Efgartigimod IV · University Health Network, Toronto · Phase 3
2026-09-06
Trial status changed: Recruiting → Unknown
NCT06881173 The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis · Cheng, yu-ting

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-14 NCT07818291 An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR… Shanghai Lanyi Therapeutics Co., Ltd. new Phase 1
2026-08-12 NCT07761026 AXIS MG Patient Registry Autoimmune Neurology Alliance new
2026-07-21 NCT07717281 PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new
2026-07-20 NCT07714798 Universal STAR-T Cell Injection in Generalized Myasthenia Gravis Daishi Tian new Phase 1
2026-06-30 NCT07676266 A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy The Affiliated Hospital of Qingdao University new Phase 1
2026-06-29 NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… TG Therapeutics, Inc. new Phase 2

Active trials by phase

Early Phase 1
9
Phase 1
16
Phase 1/2
8
Phase 2
12
Phase 2/3
10
Phase 3
27
Phase 4
7
Not charted: 70 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 159

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07246564 Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese… UCB Biopharma SRL Recruiting 2026-09-11
NCT07072988 Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia… Centre Hospitalier Universitaire de Nice Recruiting 2026-09-03
NCT07221838 A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia… Alexion Pharmaceuticals, Inc. Recruiting 2026-04-09
NCT06909214 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With… argenx Recruiting 2026-03-10
NCT06860633 Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod University of Colorado, Denver Recruiting 2025-07-11
NCT06723548 Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis First Affiliated Hospital of Wenzhou Medical University Not Yet Recruiting 2024-12-09
NCT06688253 Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis Rambam Health Care Campus Not Yet Recruiting 2024-11-14
Phase 3
NCT07463521 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With… UCB Biopharma SRL Recruiting 2026-09-11
NCT07596784 Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized… Alexion Pharmaceuticals, Inc. Recruiting 2026-09-11
NCT07647510 A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis… Dianthus Therapeutics Recruiting 2026-09-01
NCT07215949 Zilucoplan for Severe gMG Exacerbations Miriam Freimer Recruiting 2026-08-28
NCT07217587 Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized… Janssen Research & Development, LLC Recruiting 2026-08-28
NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Recruiting 2026-08-12
NCT07039916 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe… Immunovant Sciences GmbH Recruiting 2026-07-30
NCT06744920 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus… Novartis Pharmaceuticals Recruiting 2026-07-29
NCT04951622 A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis Janssen Research & Development, LLC Recruiting 2026-07-27
NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Vor Biopharma Recruiting 2026-06-18
NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) RemeGen Co., Ltd. Recruiting 2026-04-09
NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+… Alexion Pharmaceuticals, Inc. Recruiting 2026-04-01
NCT06342544 Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular… Fondation Ophtalmologique Adolphe de Rothschild Recruiting 2026-01-21
NCT05868837 Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting 2025-08-01
NCT06765161 Efgartigimod in IVIG Dependent Myasthenia Gravis Patients Clinique Neuro-Outaouais Recruiting 2025-07-29
NCT06799247 Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach… Cartesian Therapeutics Active, Not Recruiting 2026-09-01
NCT07465289 A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult… UCB Biopharma SRL Not Yet Recruiting 2026-08-25
NCT06540144 An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric… UCB Biopharma SRL Enrolling by Invitation 2026-08-14
See all 159 active Myasthenia Gravis trials with filters →

Top sponsors by active trials in this area

argenx (12) · Alexion Pharmaceuticals, Inc. (8) · UCB Biopharma SRL (7) · Centre Hospitalier Universitaire de Nice (5) · Tongji Hospital (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (4) · Huashan Hospital (4) · AstraZeneca (3) · Cartesian Therapeutics (3) · Janssen Research & Development, LLC (3)

Get alerts when Myasthenia Gravis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free